Arthritis Research Campaign

(Company Number: 490500) (Charity Number: 207711)

Report and Financial Statements

30 September 1999

Act 1942

A25
COMPANIES HOUSE

A44 COMPANIES HOUSE 0404 31/03/00

23/03/00

Head Office

Copeman House

St Mary's Court

St Mary's Gate

Chesterfield

Derbyshire S41 7TD

Telephone: 01246 558033

Fax: 01246 558007

Email: info@arc.org.uk

Website: www.arc.org.uk

Registered Charity Number: 207711

Patron

HRH The Duchess of Kent

President

Lord Lewis of Newnham

Honorary Vice Presidents to the Campaign

Michael Andrews CBE

Professor Eric Bywater CBE

His Grace the Duke of Devonshire PC, MC

Dr Alan Dixon

Dr Frank Dudley Hart

The Lady Jane Grosvenor

Dr Eric Hamilton

Dr Ken Lloyd

The Rt Hon The Baroness Macleod of Borve DL

The Lord Richardson

Dr Tom Scott

Board of Trustees

Dr B Ansell CBE

Dr C G Barnes (Acting Chairman) (resigned 28 July 1999)

Sir Richard Butler (Vice Chairman)

Dr P W M Copeman

O N Dawson Esq (Vice Chairman)*

Professor P A Dieppe

Professor T Duckworth

Dame Mary Glen Haig

Professor H J F Hodgson

R E Holland Esq*

J C Maisey Esq*

Professor G Nuki

Professor R D Sturrock (Chairman from 28 July 1999)

A C Torry Esq*

Chief Executive

Fergus Logan

Auditors

PricewaterhouseCoopers

Victoria House

76 Milton Street

Nottingham NG1 3QY

Bankers

NatWest plc

5 Market Place

Chesterfield

Derbyshire S40 1TJ

Investment Managers

Framlington Investment Management Limited

155 Bishopsgate

London

EC2M 3XJ

Solicitors

Hempsons

33 Henrietta Street

London

WC2E 8NH

^{*} Members of the Finance Committee

The Campaign is governed by the Board of Trustees which meets four times a year and for the purposes of the Companies Act 1985 act as Directors of the charity. They are supported by the committees listed below.

Scientific Co-ordinating Committee
Standing Committee for the Development of Academic Rheumatology
Fellowship Committee
Research Committee
Education Committee
Infrastructure Support Committee

The members of these committees, who receive no remuneration for their services in that capacity, are included at the end of the report and financial statements..

Statement of Responsibilities

Company law requires the Members of the Board of Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Campaign and of the income and expenditure of the Campaign for that period. In preparing those financial statements, the members are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Campaign will continue business.

The Members of the Board of Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the Campaign and to enable them to ensure that the financial statements comply with the Companies Act 1985. They are also responsible for safeguarding the assets of the Campaign and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Charitable Objectives

Arthritis Research Campaign ("the Campaign") is a registered charity with three objectives:

- To advance the study of and research into the causes, treatment and cure of arthritis and other rheumatic disease and disseminate the useful results of that research.
- To advance the education of the public by promoting the teaching of rheumatology and further understanding
 of rheumatic disease among medical students and practitioners and other persons involved in the treatment of
 rheumatic disease.
- To advance the education of the public in all matters relating to rheumatic disease including those persons suffering from the disease.

Review of the Year

Research

The Campaign continues to fund a wide-ranging programme of independently reviewed research comprising longer-term academic posts in rheumatology; five year programmes to support units in medical schools; project grants; and Fellowships for scientists and clinicians.

During the year 200 grants totalling £15.3 million were awarded, an increase compared with 1998 of £2.9 million.

The Campaign also continues to support the Kennedy Institute of Rheumatology in London with funding allocated on a five year basis, the next review due in 2002. The Institute received £2.9 million in 1999.

The second quarter of the year 2000 should finally see the granting of the UK and European licence of the new anti-TNF drug, Remicade, which could have a significant impact on the quality of life for many sufferers of severe rheumatoid arthritis.

Remicade, whose experimental name was cA2, is the direct result of many years of pioneering work by scientists at the Kennedy Institute, led by its director Professor Ravinder Maini. Professor Maini and his colleague Professor Marc Feldmann have jointly been awarded the prestigious Crafoord Prize by the Royal Swedish Academy for Sciences – which also awards the Nobel Prize – for their groundbreaking work in developing the new anti-TNF therapies.

The ARC Epidemiology Research Unit in Manchester is also funded on a five year basis and in 1999 received £1.6 million. This funding will be reviewed in 2003.

In conjunction with the British Society for Rheumatology, clinical trials into a number of arthritic conditions are due to start within the next twelve months. Some initial expenditure has been charged to the Clinical Trials Fund this year and we expect this to increase substantially over the next few years as the trials progress.

Education

A number of new patient information booklets were published during the year bringing the total number of publications to 68. These are sent to individuals, GP's, hospitals and other health service professionals on request, and 2 million were distributed during the year.

Another initiative has been to fund an interactive web-site for trainee doctors who wish to educate themselves in all aspects of rheumatology. This is in addition to our own web-site which continues to attract an increasing number of enquiries.

Fundraising

It was a year when two enduringly popular ARC fundraising events did even better than ever. Tea Week, with hundreds of branches holding tea parties, raised nearly £50,000, while the Grand Draw beat all previous years with a total of £125,000.

During 1999, together with a number of other charities, we launched our own free internet access service which will provide an additional source of income in future years.

Review of the year ... convid

Finance

Total income of £21 million was £1.8 million less than 1998. A decrease in legacies accounted for £1.2 million, and voluntary fundraising branches £0.6 million.

During the year we carried out a restructuring of our branch support network with the view of continuing to support our branch volunteers but at a lower cost. We anticipated a reduction in income from branches but after taking into account the reduced costs the net result this year has been neutral. The full effect of these changes will become apparent in future years when the ratio of branch support costs to income is substantially reduced.

In addition to these changes we established during the year a regional fundraising department which raised £0.2 million in the first nine months of its operation.

Total fundraising and administration costs at 12.2% of voluntary income were held at last year's level.

Reserves

It is the Campaign's policy to maintain a constant level of long-term research expenditure, in accordance with its objectives, notwithstanding any fluctuations in income.

The Campaign has adopted a policy, which it believes is prudent, of holding reserves that equate to between six and twelve months of the following year's estimated direct charitable expenditure. Reserves of £12 million at the year-end are consistent with this policy.

Year 2000

The Campaign has taken into consideration the year 2000 issue. No significant costs have been incurred to date and the Trustees do not consider any significant costs will be incurred.

Employees

The Campaign is an equal opportunities employer and at all times gives full and fair consideration to applications for employment made by disabled persons. The Campaign provides employees with information on matters of concern to them.

Auditors

PricewaterhouseCoopers have expressed their willingness to continue in office. A resolution proposing their reappointment and authorising the Campaign to fix their remuneration will be put to the Annual General Meeting.

Finally, on behalf of the Trustees, I would like to extend my warmest thanks to Dr Colin Barnes, who stepped into the breach left by the death of Professor Verna Wright and served as the Acting Chairman of the Campaign from March 1998 to July 1999.

By order of the Board of Trustees

Professor R D Sturrock Chairman of the Board of Trustees

Company number: 490500

10 March 2000

Registered charity number: 207711



PricewaterhouseCoopers

Victoria House 76 Milton Street Nottingham NG1 3QY Telephone +44 (0) 115 947 3000 Facsimile +44 (0) 115 947 2660

Page 6

Report of the Auditors to the Members of the Board of Trustees of Arthritis Research Campaign

We have audited the financial statements on pages 7 to 25 which have been prepared under the historical cost convention as modified by the revaluation of investments and the accounting policies set out on pages 12 to 13.

Respective responsibilities of directors and auditors

The directors who also act as trustees for the charitable activities of Arthritis Research Campaign are responsible for preparing the Annual Report, including as described on page 2 the financial statements. Our responsibilities, as independent auditors, are established by statute, the Auditing Practices Board and our profession's ethical guidance.

We report to you our opinion as to whether the financial statements give a true and fair view and are properly prepared in accordance with the Companies Act. We also report to you if, in our opinion, the directors' report is not consistent with the financial statements, if the company has not kept proper accounting records, if we have not received all the information and explanations we require for our audit, or if information specified by law regarding directors' remuneration and transactions is not disclosed.

We read the other information contained in the Annual Report and consider the implications for our report if we become aware of any apparent misstatements or material inconsistencies with the financial statements.

Basis of audit opinion

We conducted our audit in accordance with Auditing Standards issued by the Auditing Practices Board. An audit includes examination, on a test basis, of evidence relevant to the amounts and disclosures in the financial statements. It also includes an assessment of the significant estimates and judgements made by the directors in the preparation of the financial statements, and of whether the accounting policies are appropriate to the company and group's circumstances, consistently applied and adequately disclosed.

We planned and performed our audit so as to obtain all the information and explanations which we considered necessary in order to provide us with sufficient evidence to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or other irregularity or error. In forming our opinion we also evaluated the overall adequacy of the presentation of information in the financial statements.

Opinion

In our opinion the financial statements give a true and fair view of the state of the charitable company and the group's affairs at 30 September 1999 and of its net outgoing resources, including its income and expenditure and cash flows, for the year then ended and have been properly prepared in accordance with the Companies Act 1985.

PricewaterhouseCoopers

Chartered Accountants and Registered Auditors Nottingham 10 March 2000

PricewaterhouseCoopers is the successor partnership to the UK firms of Price Waterhouse and Coopers & Lybrand. The principal place of business of PricewaterhouseCoopers and its associate partnerships, and of Coopers & Lybrand, is 1 Embankment Place, London WC2N 6NN. The principal place of business of Price Waterhouse is Southwark Towers, 32 London Bridge Street, London SE1 9SY. Lists of the partners' names are available for inspection at those places.

	Note	1999 £'000	1998 £7000
Income			W. V. V. V.
Fundraising Legacies	4	3,949	4,381
Legacies		14,165	15.363
Total voluntary income		18,114	19,744
Trading - gross income	5	1,562	1,702
Investment income	6	1,361	1,406
Total income		21,037	22,852
Expenditure			
Direct Charitable Expenditure (see note 10):			
Research grants awarded	7&22	14,877	11,954
Capital grants	2&21	452	501
Research centres	8	4,647	4,403
Education		772	922
Support costs		253	257
		21,001	18,037
Trading and Investment Expenditure:			
Trading operating costs	5	1,470	1,450
Investment management fees		125	
		1,595	1,561
Other Expenditure:			
Fundraising and publicity		1,926	2,186
Administration		291	233
		2,217	2,419
Total expenditure	10	24,813	22,017
Net (outgoing)/incoming resources for the year	3	(3,776)	835
Net realised and unrealised investment gains/(losses) in the year	3	4,695	(1,352)
The regised and differenced investment gains/(105505) in the year		4,073	\$ 5 g. " a / day 1
Net Movement in Funds for the year		919	(517)
Fund Balances at 1 October 1998		21,678	22,195
Fund Balances at 30 September 1999		22,597	21,678

There is one immaterial restricted fund within the Group (see note 20).

The notes on pages 12 to 25 form part of these financial statements.

	Note	£'000	1999 £'000	£'000	1998 €°000
Fixed assets					
Tangible assets	11		6,975		7.036
Investments	12		43,338		36,826
			50,313		43,862
Current assets					
Stocks for resale		45		45	
Sundry debtors	13	331		350	
Cash on deposit and in hand		2,815		3,665	
			3,191		4,060
Current liabilities - Amounts falling due within					,
one year					
Bank overdraft		(285)		(430)	
Sundry creditors and accruals	14	(94)		(321)	
Grant payments due within one year	2&7	(11,601)		(10,962)	
			(11,980)		(11,713)
Net current liabilities			(8,789)		(7,653)
Total assets less current liabilities			41,524		36,209
Liabilities - Amounts falling due over one year					
Grant payments falling due after more than one year	2&7		(18,927)		(14,531)
			22,597		21,678
Funds					
General Research Reserve	3		12,060		3,407
Investment Reserve	3		· -		7.124
Designated Funds	3&15		10,537		11,147
			22,597		21,678

Approved by the Trustees on 10 March 2000

Professor R D Sturrock

Chairman of the Board of Trustees

The notes on pages 12 to 25 form part of these financial statements.

	Note	£'000	1999 £'000	£'000	1998 £' 0 00
Fixed assets					
Tangible assets	11		6,975		7.036
Investments	12		43,588	-	37,076
		·	50,563		44.112
Current assets					
Sundry debtors	13	315		345	
Cash on deposit and in hand		2,620		3,445	
			2,935		3,790
Current liabilities - Amounts falling due within one year					
Bank overdraft		(285)		(430)	
Sundry creditors and accruals	14	(88)		(301)	
Grant payments due within one year	2&7	(11,601)		(10,962)	
			(11,974)		(11,693)
Net current liabilities			(9,039)		(7.903)
Total assets less current liabilities			41,524		36.209
Liabilities - Amounts falling due over one year					
Grant payments falling due after more than one year	2&7		(18,927)		(14.531)
			22,597		21.678
Funds					
General Research Reserve	3		12,060		3,407
Investment Reserve	3		-		7,124
Designated Funds	3&15		10,537		11,147
			22,597		21,678

Approved by the Trustees on 10 March 2000

Professor R D Sturrock

Chairman of the Board of Trustees

The notes on pages 12 to 25 form part of these financial statements.

	1999 £'000	1998 £'000
Net cash (outflow)/inflow from operating activities (Note a)	(63)	2,737
Returns on investments and servicing of finance (Note b)	1,361	1,406
Capital expenditure and financial investment (Note b)	(2,184)	(1,771)
(Decrease)/increase in cash	(886)	2,372
Reconciliation of net cash flow to movement in net funds (Note c)		
(Decrease)/increase in cash in the period and movement in net funds	(886)	2,372
Net funds at 1 October 1998	5,556	3,184
Net funds at 30 September 1999	4,670	5,556

Notes to the group cash flow statement

a Reconciliation of net surplus to net cash inflow from operating activities

	1999	1998
	£'000	£'000
Net (deficit)/surplus	(3,776)	835
Depreciation charge	246	239
Loss/(profit) on disposal of fixed assets	1	(6)
Investment income	(1,361)	(1.406)
Decrease in stocks	-	LO
Decrease in debtors	19	19
(Decrease)/increase in creditors	(227)	73
Research/capital grants awarded during the year	15,329	12,455
Research grants paid during the year	(10,294)	(9,482)
Net cash (outflow)/inflow from operating activities	(63)	2,737

b Analysis of cash flows for headings netted in the cash j	Tow statement		, in the second
		199 £'00	
Returns on investment and servicing of finance Interest received		22	20 256
Investment income received		1,14	
Net cash inflow for returns on investments and servicing of	finance	1,36	51 1,406
Capital expenditure and financial investment		(12.0)	10) /53 3331
Purchase of investments Sale of investments		(12,80 10,81	
Purchase of tangible fixed assets Sale of tangible fixed assets		(18	
Net cash outflow for capital expenditure and financial inves	stment	(2,18	34) (1.771)
c Analysis of changes in net funds			
	As I October 1998	Cash flows	At 30 September 1999
	£'000	£'000	£'000
Cash on deposit and in hand	3,665	(850)	2,815
Bank overdraft	(430)	145	(285)
Cash deposits included in investments (see note 12)	2,321	(181)	2,140
Total	5.556	(886)	4,670

1 Legal Structure

The Campaign is a company limited by guarantee, the liability of the members of the Board of Trustees being limited to £1 each.

2 Accounting Policies

Basis of Accounting

The financial statements comply with the Statement of Recommended Practice - Accounting by Charities - issued by the Charity Commissioners in October 1995, and applicable accounting standards.

The consolidated financial statements which show the results of the Campaign and its trading subsidiary ARC Trading Limited, have been prepared under the historical cost convention as modified by the revaluation of investments at market value.

The Campaign has not presented its own statement of financial activities as permitted by Section 230 of the Companies Act 1985. The net increase in funds dealt with in the financial statements of the Campaign was £921,000.

Income and Expenditure

Income from all sources is accounted for when received, and expenditure on an accruals basis. A proportion of management and administration costs have been allocated to charitable and fund raising activities on the basis of the number of head office personnel supporting that activity. Expenditure not apportioned above relates to central administration costs, including the general management of the Campaign and other expenditure incurred to attain compliance with constitutional and statutory requirements.

Grants Awarded

Grants awarded are included in the financial statements at the time the grant is approved. Payments are made over a period of up to five years and amounts remaining due are shown as liabilities in the balance sheet.

Fixed Assets

The Campaign's tangible fixed assets are stated at cost.

Depreciation

Depreciation of tangible assets is provided on a straight line basis at the rates set out below which are sufficient to write them down to their residual value over their estimated useful lives.

Freehold property - 2%
Fixtures and fittings - 10% - 25%
Computer equipment - 20% - 33%
Motor vehicles - 25%

Freehold land is not depreciated.

2 Accounting Policies....com'd

Funds

There are four designated funds which represent amounts set aside at the Campaign's discretion for various purposes.

- Academic Rheumatology Fund to fund capital projects and endowments which promote the establishment of Rheumatology Research Units in the United Kingdom. Expenditure relating to this fund is shown as a capital grant in the statement of financial activities.
- 2 Clinical Trials Fund to fund selected clinical trials in rheumatic disease jointly with the British Society for Rheumatology.
- Fellowship Fund to support three named fellowships W S C Copeman, Michael Mason and Dorothy Eden which give grants to UK clinicians and scientists enabling them to develop new techniques at centres of excellence overseas.
- Fixed Asset Fund represents the net book value of fixed assets held by the Campaign for its own use.

Investments

Investments are shown in the balance sheet at their market value. Both realised and unrealised movements in market value from one year end to another are taken to the General Research Reserve. The market value of investments is determined, at the balance sheet date, as follows:

UK Listed

Stock Exchange middle market prices

Overseas Listed

Stock Exchange middle market prices

Authorised Unit Trusts

Published bid prices

Stock

Stock is valued at the lower of cost and net realisable value.

Foreign Currency

All assets and liabilities in foreign currencies have been translated into sterling at the rates of exchange ruling at the balance sheet date.

Pensions

Pension contributions which are explained in note 17 are charged to the income and expenditure account in the period in which they become payable.

Leases

Rental costs under operating leases are charged to the income and expenditure account.

3 Movement in Funds and Total Recognised Gains and Losses

	General Research Reserve £'000	Investment Reserve £'000	Designated Funds £'000	Total £'000
Net outgoing resources for the year	(3,776)	-	-	(3,776)
Investment reserve balance at 30 September 1998	7,124	(7,124)	-	-
Net realised and unrealised investment gains	4,695	-	-	4,695
Transfer from Designated Funds (note 15)	610		(610)	
Total recognised gains/(losses) for the financial year	8,653	(7,124)	(610)	919
Balance sheet at 30 September 1998	3,407	7,124	11,147	21,678
Balance sheet at 30 September 1999	12,060	-	10,537	22,597

The Investment Reserve previously represented the unrealised surplus on investments which is now included in the General Research Reserve.

4 Fundraising

	1999	1998
	£'000	£7000
Donations	1,766	1,781
Branch Fundraising	1,960	2,600
Regional fundraising	223	
	3,949	4,381

Net income	5 Trading Income					
Operating costs (956) (511) (3) (1,470) (1,450) Net income 5 62 25 92 252 6 Investment Income 1999 1998 £'000 £'0000 £'0000 £'0000 £'0000 £'0000 £'			mail order	promotions		
6 Investment Income 1999 £*000 1998 £*000 £*000 £*000 £*000 £*000 Property - 24 Bank interest 220 255 1,361 1.406 7 Research Grants 1999 £*000 £*000 Armounts outstanding at 1 October 25,493 22,520 Grants awarded during the year (Note 22) 14,877 11,954 Capital grants awarded during the year (Note 21) 452 501 Amounts paid during the year (10,294) (9.482) Amount outstanding at 30 September 30,528 25,493 Comprising: - Payments falling due within one year 11,601 10,962 - Payments falling due after one year 18,927 14,531						
1999 1998 £'000 £'000 £'000	Net income	5	62	25	92	282
Dividends and fixed interest 1,141 1,126 Property - 24 Bank interest 220 256 7 Research Grants 1 1,361 1.466 7 Research Grants 1 1999 £ 1998 £ 1900 £ 1900 £ 1900 £ 1900 £ 1900 £ 1900 £ 1900 £ 1900 £ 25,20 Grants awarded during the year (Note 22) 14,877 11,954 Capital grants awarded during the year (Note 21) 452 501 Amounts paid during the year (10,294) (9,482) Amount outstanding at 30 September 30,528 25,493 Comprising:	6 Investment Income				•	
Property Bank interest - 24 220 256 7 Research Grants 1,361 1.406 7 Research Grants 1999 1998 £'000 £'000 Amounts outstanding at 1 October 25,493 22,520 Grants awarded during the year (Note 22) 2 2,5493 22,520 14,877 11,954 25 2501 Amounts paid during the year (Note 21) 452 501 Amounts paid during the year (Note 21) 452 501 30,528 25,403 Amount outstanding at 30 September 30,528 25,403 Comprising: - Payments falling due within one year - Payments falling due after one year 11,601 10,962 10,962 11,531 11,50						
Bank interest 220 256 1,361 1.406 7 Research Grants 1999 £*000 1998 £*000 Amounts outstanding at 1 October 25,493 22,520 Grants awarded during the year (Note 22) 14,877 11,954 Capital grants awarded during the year (Note 21) 452 501 Amounts paid during the year (10,294) (9,482) Amount outstanding at 30 September 30,528 25,493 Comprising:					1,141	
7 Research Grants 1999 1998 £'000 £'0000 Amounts outstanding at 1 October 25,493 22,520 Grants awarded during the year (Note 22) 14,877 11,954 Capital grants awarded during the year (Note 21) 452 501 Amounts paid during the year (10,294) (9,482) Amount outstanding at 30 September 30,528 25,493 Comprising: Payments falling due within one year 11,601 160,962 Payments falling due after one year 18,927 14,531 Amount outstanding due after one year		,			220	
1999 1998 £'000 £'000 Amounts outstanding at 1 October 25,493 22,520 Grants awarded during the year (Note 22) 14,877 11,954 Capital grants awarded during the year (Note 21) 452 501 Amounts paid during the year (10,294) (9,482) Amount outstanding at 30 September 30,528 25,493 Comprising: Payments falling due within one year 11,601 10,962 Payments falling due after one year 18,927 14,531 					1,361	1.406
£'000 £'000 Amounts outstanding at 1 October 25,493 22,520 Grants awarded during the year (Note 22) 14,877 11,954 Capital grants awarded during the year (Note 21) 452 501 Amounts paid during the year (10,294) (9,482) Amount outstanding at 30 September 30,528 25,493 Comprising: Payments falling due within one year Payments falling due after one year 11,601 10,962 Payments falling due after one year Amount outstanding at 30 September	7 Research Grants					
Grants awarded during the year (Note 22) Capital grants awarded during the year (Note 21) Amounts paid during the year (10,294) Amount outstanding at 30 September Comprising: - Payments falling due within one year - Payments falling due after one year 11,601 10,962 14,531						
Capital grants awarded during the year (Note 21) Amounts paid during the year (10,294) Amount outstanding at 30 September 30,528 25,493 Comprising: - Payments falling due within one year - Payments falling due after one year 11,601 10.962 - Payments falling due after one year 18,927 14,531	Amounts outstanding at 1 October				25,493	22,520
Amount outstanding at 30 September 30,528 25,493 Comprising: - Payments falling due within one year 11,601 10.962 - Payments falling due after one year 18,927 14,531	Capital grants awarded during the year (No	te 21)			452	501
- Payments falling due within one year 11,601 10.962 - Payments falling due after one year 18,927 14,531						
- Payments falling due within one year 11,601 10.962 - Payments falling due after one year 18,927 14,531			, , , , , , ,			-
30,528 25,493	- Payments falling due within one year					
					30,528	25,493

8 Research Centres 1999 1998 £'000 £'000 Kennedy Institute of Rheumatology - core grant 2,865 2,865 ARC Epidemiology Research Unit 1,628 1,378 Depreciation 134 133 Other costs 20 27 4,647 4.403

(a) Kennedy Institute of Rheumatology

The Campaign provides the Kennedy Institute with rent free accommodation. The core grant of £2.9 million is reviewed at 5 yearly intervals and is next due for review on 1 October 2002.

The full statutory accounts of the Kennedy Institute are available from the company secretary at:

Kennedy Institute of Rheumatology 1 Aspenlea Road Hammersmith LONDON W6 8LH

(b) ARC Epidemiology Research Unit

This unit is based at the University of Manchester and the current grant of £1.6 million per annum was fixed for a period of 5 years commencing 1 October 1998.

9 Income and Expenditure

The income and expenditure account is arrived at after charging/(crediting) the following:

	1999 £'000	1998 L'000
Depreciation of tangible fixed assets Loss/(profit) on disposal of fixed assets Auditors remuneration (for audit services only) Amounts paid under operating leases	246 1 23 435	239 (6) 23 478

The audit fee included above in respect of the Campaign is £19,000 (1998: £18,500).

10 Analysis of Total Expenditu	ire					
		Staff	Depre-		1999	1998
	Awards £'000	Costs £'000	ciation £'000	Other £'000	Total £'000	Total £'000
Direct Charitable						
Research Grants	14,877	-	-	_	14,877	11,954
Capital Grant	452	_	-	_	452	501
Research Centres	4,493	_	134	20	4,647	4,403
Education	-	147	9	616	772	922
Support Costs	-	140	6	107	253	257
Other Expenditure						
Head Office Fundraising and Publicity		267	18	588	873	660
Branch Fundraising	-	340	19	412	771	1,412
Regional Fundraising	-	163	16	103	282	
Restructuring			-	-	_	y y co
	-	770	53	1,103	1,926	2.186
Management and Administration	_	157	32	102	291	233
Trading and Investment	-	392	12	1,191	1,595	1,561
	19,822	1,606	246	3,139	24,813	22,017
Staff Costs					-	
					1999	1998
					2000	£'000
Salaries				t	,373	1,555
Social security costs				1	121	139
Other pension costs					96	85
Other staff costs					16	18
Restructuring		_			- -	90
				1	,606	*,887

10 Analysis of Total Expenditure....com?d

The average number of employees during the year was:

	1999 Number	1998 Number
Education	5	3
Support	4	4
Fundraising and publicity	29	40
Management and administration	14	paner)
Shops and trading	38	46
	90	104

The number of employees whose emoluments (excluding pension contributions) were above £40,000 are as follows:

	1999	1998
Between £60,000 - £70,000	1	\$ 8

The Trustees of the Campaign receive no remuneration for their services in that capacity, but have been reimbursed for expenses directly incurred in carrying out their activities as Trustees at a cost of £1,993 (1998: £1,329).

11 Tangible Assets

Group and Campaign

	Freehold Land and Buildings £'000	Fixtures and Fittings £'000	Computer Equipment £'000	Motor Vehicles £'000	Total £'000
Cost					
At 1 October 1998	7,574	225	273	69	8,141
Additions	30	23	15	118	186
Disposals	<u> </u>	(38)	(61)		(99)
At 30 September 1999	7,604	210	227	187	8,228
Depreciation					
At 1 October 1998	718	171	202	14	1,105
Charge for the year	155	21	42	28	246
Released on disposals	<u>-</u>	(38)	(60)	-	(98)
At 30 September 1999	873	154	184	42	1,253
Net book amount					
At 30 September 1999	6,731	56	43	145	6,975
At 30 September 1998	6,856	54	71	55	7,036

The net book amount at 30 September 1999 represents tangible fixed assets used for:

	1999 £'000	1998 £'000
Direct Charitable purposes Other purposes	5,965 1,010	6,099 937
	6,975	7,036

12 Investments

Group

	Market Value		(Sost
	1999	1998	1999	1998
	£'000	£'000	£'000	£'000
Listed securities				
- Fixed interest	7,591	7.140	7,548	6,406
- UK	21,393	18,396	15,955	13,352
- Overseas	8,423	5,690	6,184	4,921
Authorised unit trusts	3,791	2,674	1,508	2,030
	41,198	33,900	31,195	26.759
Freehold properties	-	605	_	622
Cash deposits	2,140	2,321	2,140	2,321
	43,338	36,826	33,335	29,702
Comprising:				
Investments	41,198	34,505	31,195	27,381
Cash deposits	2,140	2,321	2,140	2.321
			"	
Campaign:	42.220	27 026	22.225	00.700
As stated above for the group	43,338	36,826	33,335	29,702
Investment in subsidiary (ARC Trading Limited)	250	250	250	250
	43,588	37,076	33,585	29,952

12 Investments....com'd

Group.....ent'd

Movement on investments for the Group:

	1	Freehold	
	Total £'000	and authorised unit trusts £'000	property £'000
At 1 October 1998 at market value	34,505	33,900	605
Additions at cost	12,808	12,808	-
Proceeds of sale	(10,810)	(10,226)	(584)
Net investment gains	4,695	4,716	(21)
At 30 September 1999 at market value	41,198	41,198	-

Realised gains based on historic cost amounted to £1,836,000 (1998: £1,996,000).

The portfolio of securities is managed on the Campaign's behalf by Framlington Investment Management Limited, who are also responsible for the custody of the securities and unit trusts.

ARC Trading Limited:

	1999 £'000	1998 £'000
Investment in subsidiary (ARC Trading Limited)	250	250

ARC Trading Limited is a 100% subsidiary of the Campaign, incorporated in England and is principally engaged in the sale of Christmas cards and other gift items by mail order catalogue and through the Campaign's voluntary branches. Surplus stock is sold through the Campaign's shops and storage and distribution services are also provided to the Campaign for which charges are levied at commercial rates. The net profit is covenanted to the Campaign.

The auditors' report contained no qualifications, and the Directors' Report and Financial Statements, for the year ended 30 June 1999, have been filed with the Registrar of Companies. The 30 June year end is used to conform to the company's trading cycle.

13 Sundry Debtors

	Group		Campaig	n
	1999	1998	1999	7998
	£'000	£1000	£'000	£.000
Amount due from subsidiary company	_	~	23	
Income tax/tax credits	50	59	50	59
VAT	15	14	15	34
Prepayments	153	176	122	158
Other debtors	113	101	105	94
	331	350	315	345

14 Sundry Creditors and Accruals

	Group		Campaig	n
	1999	1998	1999	7998
	£'000	£1000	£'000	£.000
Other creditors	27	105	27	90
Accruals	67	216	61	211
	94	375	88	301

15 Designated Funds - Group and Campaign

	Academic Rheumatology Fund £'000	Clinical Trials Fund £'000	Fellowship Fund £'000	Fixed Asset Fund £'000	Total £'000
Balance at 1 October 1998	2,406	1,500	205	7,036	11,147
Expenditure Income Other transfers from General Research	(452)	(87) -	(93) 21	-	(632) 21
Reserve	-	_	62	(61)	1_
Total transfers from General Research Reserve	(452)	(87)	(10)	(61)	(610)
Balance at 30 September 1999	1,954	1,413	195	6,975	10,537

Details concerning the designated funds are given in note 2.

16 Fixed Asset Fund 1999 1998 £'000 £'000 Balance at 1 October 7,036 7,182 Additions 186 108 Disposals (1)(15)Depreciation (246)(239)Balance at 30 September 6,975 7,036

17 Pension Arrangements

The Campaign together with the majority of its employees, makes annual contributions to two pension funds whose assets are held separately from those of the Campaign in independently administered funds. One is a defined contribution scheme managed by Scottish Amicable Life Assurance Society Limited and the other a defined benefit scheme managed by University Superannuation Scheme Limited.

The pension charge represents contributions payable by the Campaign to the funds and amounted to £96,000 (1998: £85,000). Contributions totalling £85,000 (1998: £93,000) were prepaid at the year end and are included in debtors.

18 Operating Leases

Payments on operating leases during the year amounted to £435,000 (1998: £478,000). The expected leasing charges for the next financial year amount to £390,000 (1998: £429,000). This amount comprises leases due to expire in:

	Proper	rty	Vehicl	es	Total	l
	1999 [~]	1998	1999	1998	1999	1998
	£'000	£,000	£'000	£,000	£'000	£'000
Less than 1 year	22	22	19	20	41	42
1 to 5 years	115	131	7	4()	122	171
Over 5 years	227	216		~	227	216_
	364	369	26	60	390	429

19 Related Party Transactions

There were no related party transactions during the year other than those with Kennedy Institute (note 8) and the Campaign's trading subsidiary, ARC Trading Limited. The results of ARC Trading Limited have been consolidated with those of the Campaign.

20 Restricted Funds

The Arthritis Research Campaign is receiving funding from the National Lotteries Board of £96,716, over a three year period from 19 March 1997, for a research project validating a new bone measurement technique. This grant was awarded by the Campaign to the University of Aberdeen in July 1996 and was included in the Campaign's accounts for the year ended 30 September 1996. The balance at 30 September 1999 is included in the grant payments due within one year.

	Balance at 30	Movement	t in Funds	Balance at 30
	September 1998	Income	Expenditure	September 1999
	€.	£	£	£
O				
NATIONAL LOTTERY				
CHARITIES BOARD	(36.805)	29,796	-	(7,009)

21 Capital Grants

Two grants have been charged to the academic rheumatology fund (note 15) during the year:

	1999 £'000
- University College London	245 207
- Southampton General Hospital	207
	452

22 Grants Awarded 1999 7998 £'000 $\mathcal{E}'000$ 128 awards over £10,000 (1998: 119 awards) 14,551 12,033 72 awards less than £10,000 (1998: 98 awards) 258 375 Supplements to existing grants 512 383 Awards no longer required (444)(837) 14,877 11,954

Details of grants awarded over £10,000 are shown on the following page.

Detailed schedule of Grants Awarded in the Year

	Number of	61000
	grants	£'000
Addenbrooke's NHS Trust, Cambridge	5	292
Freemans Hospital Newcastle	1	287
Haywoods Hospital, Stoke on Trent	1	16
Imperial College, London	9	1,667
Kings College, London	10	1,237
Medical Research Council, Cambridge	2	248
Queens University of Belfast	1	17
Robert Jones & Agnes Hunt Orthopaedic Hospital, Oswestry	1	93
South Cleveland Hospital	1	28
St Albans Hospital	1	40
St Bartholomew's & Royal London Hospitals, London	7	713
St George's Hospital, London	í	64
University College, London	13	2,669
University of Aberdeen	5	2,009
University of Bath	3	187
University of Birmingham	5	762
University of Bristol	2	30
University of Derby	2	102
University of Edinburgh	2	311
University of East Anglia, Norwich	4	453
University of Glasgow	5	1,050
University of Keele	1	1,030
University of Lancaster	1	100
University of Leeds	3	184
University of Liverpool	2	266
University of Manchester	9	720
University of Newcastle upon Tyne	1	132
University of Nottingham	3	302
University of Oxford	10	1,002
University of Sheffield	3	204
University of Southampton	4	383
University of Strathclyde	í	79
University of Wales, Cardiff	7	506
University of York	1	500 58
Wexham Park Hospital, Slough	1	38 19
wennam i ark mospitar, brough	1	19
Total	128	14,551

Medical Committees

Scientific Co-ordinating Committee (SCC)

Determines scientific policies, awards programme grants, and confirms research and educational grant awards recommended by its sub-committees.

Professor Humphrey Hodgson (Chairman)

Professor David Isenberg (Vice Chairman)

Professor Peter Beverley

Professor Howard Bird

Professor Carol Black

Dr Anne Cooke

Professor Paul Gregg

Professor Tim Hardingham

Professor Stephen Holgate

Professor David Katz

Professor Mark Walport

Standing Committee for the Development of Academic Rheumatology (SCDAR)

Responsible for the endowment of chairs of rheumatology and other permanent academic posts in universities. Also considers applications for short-term senior and clinical lectureship posts in medical schools. Meets as and when developments in academic rheumatology demand. Reports to the SCC.

Dr Colin Barnes (Chairman)

Dr Barbara Ansell

Professor Paul Bacon

Dr Bryan Bourke

Professor Tim Cawston

Professor Dorian Haskard

Professor David Isenberg

Dr John Kirwan

Professor Sandy McNeish

Fellowship Sub-Committee (FSC)

Meets five times a year to interview candidates for senior, postdoctoral, clinical, clinician scientist and travelling fellowships. Also recommends PhD studentship awards. Reports to the SCC.

Professor Hill Gaston (Chairman)

Professor Graham Russell (Vice Chairman)

Dr Madeleine Devey (Scientific Secretary)

Membership varies according to the nature of the fellowship under consideration.

Education Sub-Committee

Oversees the award of various grants and bursaries, sponsorship of scientific meetings, ARC's wide range of publications, and other educational activities. Reports to the SCC.

Dr Elaine Hay (Chairman)

Dr Paul Thompson (Vice Chairman)

Dr Ade Adebajo

Dr Alison Carr

Dr Fiona Clarke

Dr Chris Deighton

Dr Susan Fraser

Dr Neil Hopkinson

Professor Brian Jolly

Professor Peter Maddison

Dr Margaret O'Sullivan

Mrs Sarah Ryan

Dr Margaret Sands

Dr David Walker

Research Sub-Committee (RSC)

Meets three times a year to consider approximately 210 applications per year for project and equipment grants. Reports to the SCC.

Professor Roger Mason (Chairman)

Professor Gabriel Panayi (Vice Chairman)

Dr Ray Boot-Handford

Professor Cyrus Cooper

Professor Steven Dower

Professor Fred Heatley

Professor Brian Henderson

Professor Mike Horton

Professor David Hukins

Professor Ian Learmonth

Professor Gill Murphy

Professor Bill Ollier

Professor Jonathan Seckl

Professor Tauny Southwood

Professor David Wraith

Medical Committees

Infrastructure Support Committee (ISC)

Meets annually to consider applications for Integrated Clinical Arthritis Centre awards and Academic Secretary Grants. Reports to the SCC.

Professor Alan Silman (Chairman)
Dr Madeleine Devey (Scientific Secretary)

Membership varies according to the nature of the applications under consideration.

Programme Grant Sub-Committee (PGSC)

Undertakes the annual review of programme grant applications, organises site visits and reports recommendations for programme grant funding to the SCC.

Professor Stephen Holgate (Chairman) Dr Madeleine Devey (Scientific Secretary)

Membership varies according to the nature of the applications under consideration.

ARC/BSR Clinical Trials Group

In conjunction with the BSR, the ARC has formed the Clinical Trials Group to promote clinical research on a multi-centre basis, with a national direction. Reports to the SCC.

Professor David Blake (Chairman)
Dr Madeleine Devey (Scientific Secretary)

Membership varies according to the trials being carried out.

Honorary Medical Secretaries

Professor Dorian Haskard Dr John Isaacs Dr Rajan Madhok Dr Richard Watts Professor Bryan Williams